Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Karboplatina nebo Olaparib pro BRcA deficitní rakovinu prostaty (COBRA)

12. listopadu 2026 aktualizováno: VA Office of Research and Development

Otevřená, multicentrická studie fáze II k porovnání účinnosti karboplatiny jako první linie následovaná olaparibem druhé linie versus olaparib jako první linie následovaná karboplatinou druhé linie v léčbě pacientů s kastračně rezistentním karcinomem prostaty obsahující homologní rekombinaci Nedostatek

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations.

Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria.

Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Study General Trial Over-view

This study is designed to help better understand treatment options compared to standard therapies for patients who have targeted DNA repair mutations and metastatic castrate resistant prostate cancer (mCRPC).

Cancer therapies are aimed at finding a way to kill the cancer cells while causing minimal damage to normal (non-cancer) cells. This often works because cancers cells grow faster than many normal cells, many treatments are aimed at to take advantage of that difference. One of the ways to do this is to damage the DNA of these more rapidly growing cells. However, if the cells have a way of repairing that damage then therapies may not work as well. Some research shows that when specific changes or mutations occur in the genes involved with repairing DNA damage, resulting cancers have responded well to drugs which damage DNA.

Olaparib is known as a PARP inhibitor and is standard of care therapy for men with BRCA altered mCRPC. Carboplatin is a synthetic antineoplastic agent which has been used in the treatment of solid tumors and BRCA related cancers. When mutations occur in critical DNA-repair genes, research has found that treatment with carboplatin is also effective.

This research is being done to determine the response of mCRPC in patients with DNA repair mutations to treatment with olaparib compared to carboplatin. This study will test whether giving one drug or the other a has a better response.

Patients wishing to participate in this study are screened for safety and health eligibility before enrolling.

This study is enrolling 100 male participants total, from across the VAMC nationally who have the following:

  • Metastatic castration-resistant prostate cancer (mCRPC)
  • Cancer that has gotten worse, after any number of first-line treatments
  • Mutations in DNA-repair genes discovered as part of a patient's routine care.

Once eligibility is determined, enrolled participants are randomized into one of two groups:

  • Group A will start with carboplatin (IV) first, given every 21 days, then have the option to switch to the second treatment with olaparib taken daily, (orally) with cycles of every 28 days.
  • Group B will start with olaparib first, taken (orally), with 28 day cycles, then have the option to switch to the second treatment with carboplatin (IV) every 21 days.

Both study drugs in this trial are currently FDA approved, and are prescribed at the participating VAMC clinical sites per institutional guidelines. Carboplatin given in IV is also given as prescribed at the participating VAMC, and administered per institutional guidelines.

Participants are monitored for health and body function, cancer progression, toxicity and life quality at every visit during the trial and at an end of treatment visit (28 days after completion of the trial or after withdrawal). For participants who respond well to treatment during the trial, additional treatment cycles may be added and the study can be extended. Participants who experience intolerable toxicity, cancer progression, or whose doctors decide to change treatment, will either be switched to the opposite study drug or withdrawn from the study.

This important trial is designed to compare response rate and duration of response using carboplatin compared to olaparib in patients who have mCRPC which contains DNA repair gene mutations.

Typ studie

Intervenční

Zápis (Odhadovaný)

100

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

    • California
      • West Los Angeles, California, Spojené státy, 90073
        • Nábor
        • VA Greater Los Angeles Healthcare System, West Los Angeles, CA
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Nábor
        • Rocky Mountain Regional VA Medical Center, Aurora, CO
        • Kontakt:
    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20422-0001
        • Nábor
        • Washington DC VA Medical Center, Washington, DC
        • Kontakt:
    • Florida
      • Bay Pines, Florida, Spojené státy, 33744-0000
        • Ukončeno
        • Bay Pines VA Healthcare System, Pay Pines, FL
      • Orlando, Florida, Spojené státy, 32827
        • Nábor
        • Orlando VA Medical Center, Orlando, FL
        • Kontakt:
    • Georgia
      • Decatur, Georgia, Spojené státy, 30033
        • Nábor
        • Atlanta VA Medical and Rehab Center, Decatur, GA
        • Kontakt:
          • Wayne Harris, MD
          • Telefonní číslo: 206147 404-321-6111
    • Idaho
      • Boise, Idaho, Spojené státy, 83702
    • Illinois
      • Chicago, Illinois, Spojené státy, 60612
        • Ukončeno
        • Jesse Brown VA Medical Center, Chicago, IL
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48105
        • Nábor
        • VA Ann Arbor Healthcare System, Ann Arbor, MI
        • Kontakt:
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55417-2309
        • Nábor
        • Minneapolis VA Health Care System, Minneapolis, MN
        • Kontakt:
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64128
        • Nábor
        • Kansas City VA Medical Center, Kansas City, MO
        • Kontakt:
          • Bruce Montgomery
          • Telefonní číslo: 206-277-6878
    • New York
      • New York, New York, Spojené státy, 10010
        • Nábor
        • Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
        • Kontakt:
      • The Bronx, New York, Spojené státy, 10468-3904
        • Ukončeno
        • James J. Peters VA Medical Center, Bronx, NY
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27705-3875
        • Nábor
        • Durham VA Medical Center, Durham, NC
        • Kontakt:
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Nábor
        • VA Portland Health Care System, Portland, OR
        • Kontakt:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19106
        • Nábor
        • Philadelphia MultiService Center, Philadelphia, PA
        • Kontakt:
    • Washington
      • Seattle, Washington, Spojené státy, 98108-1532
        • Nábor
        • VA Puget Sound Health Care System Seattle Division, Seattle, WA
        • Vrchní vyšetřovatel:
          • Robert B. Montgomery, MD
        • Kontakt:
    • Wisconsin
      • Madison, Wisconsin, Spojené státy, 53705-2254
        • Nábor
        • William S. Middleton Memorial Veterans Hospital, Madison, WI
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Mužský

Popis

Inclusion Criteria:

  1. Signed study informed consent form (ICF) and HIPAA authorization form

  2. Diagnosis of prostate cancer (pure small-cell histology or pure high-grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed)

  3. Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy

  4. mCRPC as defined by serum testosterone < 50 nanograms per milliliter (ng/ml) for patients on GnRH analogues or antagonists) and at least one of the following:

    • Prostate-specific antigen (PSA) level of at least 2 nanograms per milliliter (ng/ml) that has risen on at least 2 successive occasions at least 1 week apart
    • Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
    • Progression of metastatic bone disease on bone scan, CT or MRI with > 2 new lesions
  5. Prior therapy with abiraterone acetate, enzalutamide, apalutamide, or darolutamide

  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2 (see Appendix 3, ECOG Grading Scale)

  7. Results of previous standard DNA testing, or previous research testing, which confirms RAD51B, RAD51C, RAD51D, or RAD54L mutations (see Introduction, Section 2 for study design and previous research on targeted therapy) from primary, metastatic tumor or circulating tumor DNA, or pathogenic/likely pathogenic germline variant as assessed by a CLIA certified laboratory level assay for DNA sequencing.

  8. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • Hemoglobin > 10.0 grams per deciliter (g/dL)
    • Absolute neutrophil count (ANC) > 1.5 x 109/liter (L)
    • Platelet count > 100 x 109/L
    • Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT) < 2.5 x institutional upper limit of normal unless liver metastases are present in which case, they must be < 5x ULN
    • Patients must have creatinine clearance estimated using the Cockcroft-Gault equation of >51 mL/min: Estimated creatinine clearance =(140-age [years]) x weight (kg)/(serum creatinine (mg/dL) x 72)

Exclusion Criteria:

  1. Currently receiving active therapy for other neoplastic disorder(s)
  2. Concurrent enrollment in another clinical investigational drug or device study
  3. Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendocrine differentiation without morphologic evidence is not exclusionary)
  4. Prior treatment with platinum, mitoxantrone or PARP inhibitor for castration resistant prostate cancer
  5. Known parenchymal brain metastasis
  6. Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia)
  7. Subjects with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML
  8. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks
  9. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for phenobarbital and 3 weeks for other agents
  10. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication
  11. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of < 35 % at baseline
  12. Treatment with an investigational therapeutic within 30 days of Cycle-1
  13. Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding HIPAA authorization and/or giving of informed consent
  14. Any condition(s), medical or otherwise, which, in the opinion of the Investigators, would jeopardize either the patient or the integrity of the data obtained

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Výzkum zdravotnických služeb
  • Přidělení: Randomizované
  • Intervenční model: Crossover Assignment
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Treatment Arm 1 - Carboplatin to Olaparib

Participants are administered carboplatin AUC 5 IV first, which is administered Cycle-1, Day-1, and then every 21 days as first line therapy. For second line (crossover), olaparib is prescribed and taken orally at home, twice daily, 300 mg in 28 day cycles.

Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Ostatní jména:
  • Paraplatin

Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Ostatní jména:
  • Lynparza
Aktivní komparátor: Treatment Arm 2 - Olaparib to Carboplatin

Participants are prescribed olaparib which is taken orally at home, twice daily, 300 mg in 28 day cycles, as first line therapy. For second line (crossover), carboplatin is administered AUC 5 IV every 21 days thereafter.

Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

Ostatní jména:
  • Paraplatin

Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Ostatní jména:
  • Lynparza

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatment
Časové okno: Through duration of the study, up to 100 weeks

Progression free survival (PFS) by bone scan or measurable disease, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) to initial therapy (PFS-1L) with either study drug

Through duration of the study, up to 100 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time interval between randomization and second documented disease progression during or after second-line or death (due to any cause)
Časové okno: Through duration of the study, up to 100 weeks

Progression-free survival combined, a composite endpoint defined as the time interval between randomization and second documented disease progression reported during or after second-line or death due to any cause

Through duration of the study, up to 100 weeks
PSA measurements/response
Časové okno: Through duration of the study, up to 100 weeks

To assess PSA response to initial therapy with carboplatin vs. olaparib

Through duration of the study, up to 100 weeks
PSA measurements/response
Časové okno: Through duration of the study, up to 100 weeks

To assess PSA response duration to second line therapy with olaparib vs carboplatin

Through duration of the study, up to 100 weeks
Grade 3 and 4 toxicities in first and second-line setting
Časové okno: Through duration of the study, up to 100 weeks

To assess Grade 3 and 4 toxicities for each regimen in the first- and second-line setting

Through duration of the study, up to 100 weeks
To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer
Časové okno: Through duration of the study, up to 100 weeks

To assess cost effectiveness of carboplatin versus olaparib for the treatment of castration-resistant metastatic prostate cancer

Through duration of the study, up to 100 weeks

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Exploratory Objective - PFS
Časové okno: Through duration of the study, up to 100 weeks

To assess the PFS of patients who receive olaparib versus patients who receive carboplatin during the second-line of treatment (PFS-2L)

Through duration of the study, up to 100 weeks
Exploratory Objective - objective response rate
Časové okno: Through duration of the study, up to 100 weeks

To assess the objective response rate in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

Through duration of the study, up to 100 weeks
Exploratory Objective- objective duration of response
Časové okno: Through duration of the study, up to 100 weeks

To assess the objective duration of response in patients who receive olaparib versus patients who receive carboplatin during second-line of treatment.

Through duration of the study, up to 100 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Robert B. Montgomery, MD, VA Puget Sound Health Care System Seattle Division, Seattle, WA
  • Vrchní vyšetřovatel: Maneesh Jain, MD, Washington DC VA Medical Center, Washington, DC
  • Vrchní vyšetřovatel: Phoebe Tsao, MD MSc, VA Ann Arbor Healthcare System, Ann Arbor, MI
  • Vrchní vyšetřovatel: Ryan Burri, MD, Bay Pines VA Healthcare System, Pay Pines, FL

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. října 2019

Primární dokončení (Odhadovaný)

31. srpna 2027

Dokončení studie (Odhadovaný)

31. srpna 2027

Termíny zápisu do studia

První předloženo

26. července 2019

První předloženo, které splnilo kritéria kontroly kvality

29. července 2019

První zveřejněno (Aktuální)

30. července 2019

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • ONCA-009-18F
  • CX-18-006 (Jiné číslo grantu/financování: Veterans Affairs CSR&D Merit Review Award)
  • 19-08 (Jiný identifikátor: VA CIRB)
  • 01783 (Jiný identifikátor: MIRB (LSI))
  • 01781 (Jiný identifikátor: MIRB (National Chair))
  • 1I01CX001963-01 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .